Literature DB >> 21323562

Long-term therapy with bevacizumab in hereditary hemorrhagic telangiectasia.

Brian T Brinkerhoff, David M Poetker, Nicholas W Choong.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21323562     DOI： 10.1056/NEJMc1012774

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  10 in total

1.  Long-term therapy with bevacizumab in a patient with Glanzmann's thrombasthenia and recurrent digestive bleeding due to gastrointestinal angiodysplastic lesions.

Authors:  Raphael Marlu; J Barthelon; A Durand; N Mathieu; C Barro; V Granger; A Tatu; G Pernod; B Polack; B Bonaz
Journal:  Am J Gastroenterol       Date:  2015-02       Impact factor: 10.864

2.  A phase I first-in-human study of TRC105 (Anti-Endoglin Antibody) in patients with advanced cancer.

Authors:  Lee S Rosen; Herbert I Hurwitz; Michael K Wong; Jonathan Goldman; David S Mendelson; William D Figg; Shawn Spencer; Bonne J Adams; Delia Alvarez; Ben K Seon; Charles P Theuer; Bryan R Leigh; Michael S Gordon
Journal:  Clin Cancer Res       Date:  2012-07-05       Impact factor: 12.531

3.  Blessing for the bleeder: bevacizumab in hereditary hemorrhagic telangiectasia.

Authors:  Narendranath Epperla; William Hocking
Journal:  Clin Med Res       Date:  2014-03-25

4.  Hereditary hemorrhagic telangiectasia treated with low dose intravenous bevacizumab.

Authors:  Jee Wan Wee; Young Woo Jeon; Jun Young Eun; Han Jo Kim; Sang Byung Bae; Kyu Taek Lee
Journal:  Blood Res       Date:  2014-09-25

5.  Bevacizumab and gastrointestinal bleeding in hereditary hemorrhagic telangiectasia.

Authors:  George Ou; Cherry Galorport; Robert Enns
Journal:  World J Gastrointest Surg       Date:  2016-12-27

6.  Intermittent low-dose bevacizumab in hereditary hemorrhagic telangiectasia : A case report.

Authors:  Florian Huemer; Martin Dejaco; Christoph Grabmer; Thomas Melchardt; Daniel Neureiter; Georg Mayer; Alexander Egle; Richard Greil; Lukas Weiss
Journal:  Wien Klin Wochenschr       Date:  2017-02       Impact factor: 1.704

Review 7.  Hereditary hemorrhagic telangiectasia: diagnosis and management from the hematologist's perspective.

Authors:  Athena Kritharis; Hanny Al-Samkari; David J Kuter
Journal:  Haematologica       Date:  2018-05-24       Impact factor: 9.941

8.  Surgery of hereditary hemorrhagic telangiectasia with severe refractory gastrointestinal bleeding: A case report of a rare condition.

Authors:  Dae Ro Lim; Da Bin Kim; Hee Kyung Kim; Eung Jin Shin
Journal:  Int J Surg Case Rep       Date:  2020-06-13

9.  Bevacizumab to Treat Cholangiopathy in Hereditary Hemorrhagic Telangiectasia: Be Cautious: A Case Report.

Authors:  Quentin Maestraggi; Mohamed Bouattour; Ségolène Toquet; Roland Jaussaud; Reza Kianmanesh; François Durand; Amélie Servettaz
Journal:  Medicine (Baltimore)       Date:  2015-11       Impact factor: 1.817

10.  An international, multicenter study of intravenous bevacizumab for bleeding in hereditary hemorrhagic telangiectasia: the InHIBIT-Bleed study.

Authors:  Hanny Al-Samkari; Raj S Kasthuri; Joseph G Parambil; Hasan A Albitar; Yahya A Almodallal; Carolina Vázquez; Marcelo M Serra; Sophie Dupuis-Girod; Craig B Wilsen; Justin P McWilliams; Evan H Fountain; James R Gossage; Clifford R Weiss; Muhammad A Latif; Assaf Issachar; Meir Mei-Zahav; Mary E Meek; Miles Conrad; Josanna Rodriguez-Lopez; David J Kuter; Vivek N Iyer
Journal:  Haematologica       Date:  2021-08-01       Impact factor: 9.941
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.